Skip to main content

Ruconest FDA Approval History

FDA Approved: Yes (First approved July 16, 2014)
Brand name: Ruconest
Generic name: C1 esterase inhibitor (recombinant)
Previous Name: Rhucin
Company: Pharming Group NV
Treatment for: Hereditary Angioedema

Ruconest is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

Development timeline for Ruconest

DateArticle
Jul 17, 2014Approval FDA Approves Ruconest for Hereditary Angioedema
Feb 28, 2011Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for Rhucin Biologics License Application
Dec 28, 2010Pharming And Santarus Announce Submission Of Rhucin Biologics License Application to FDA
Jan 29, 2008Pharming Provides Update on Rhucin

See also

Ruconest (C1 esterase inhibitor (recombinant)) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer